Drug Repurposing: New Treatments for Zika Virus Infection?
To date, no antiviral agents have been approved for treating Zika virus (ZIKV) infection. Two recent drug-repurposing studies published in Cell Host & Microbe and Nature Medicine demonstrated that screening FDA-approved drugs for antiviral activity is a promising strategy for identifying therapeutics with novel activity against ZIKV infection.
Center for Complex Networks Research, Northeastern University, Boston, MA 02115, USA; Center for Cancer Systems Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: fxcheng1985@gmail.com.
Feixiong
F
Cheng
GeneTAG Technology, Inc., Atlanta, GA 30340, USA.
James L
JL
Murray
Division of Infectious Disease, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA; Research Medicine, VA Tennessee Valley Healthcare System, Nashville, TN 37212, USA.
Donald H
DH
Rubin
D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D058492:Drug Repositioning / Q000379:methods*; D006801:Humans; D015398:Signal Transduction / Q000187:drug effects; D000071244:Zika Virus / Q000187:drug effects*; D000071243:Zika Virus Infection / Q000188:drug therapy* / Q000378:metabolism
D000998:Antiviral Agents
Zika virus; antiviral; drug repurposing; mechanism-of-action